L'intérêt à découvert pour Edwards Lifesciences donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Edwards Lifesciences. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Edwards Lifesciences (NYSE:EW) Stock, Rapport sur les intérêts à découvert

Edwards Lifesciences

Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter valve technologies, surgical clips, and catheters. The firm derives about 55% of its total sales from outside the US.

Edwards Lifesciences Corporation Common Stock

Edwards Lifesciences Corp

iShares MSCI Australia Index Fund

East West Bancorp Inc

EAST WEST BANKING CORP by EAST WEST BANKING CORPORATION

iShares MSCI Canada Index Fund

ENERGY WORLD CORP LTD by Energy World Corp. Ltd.

Energy World Corp Ltd

European Wax Center, Inc. - Class A Common Stock

European Wax Center Inc

iShares Inc iShares MSCI Sweden ETF

Global X Funds Emerging Mkts Internet & E- Commerce ETF (New)

iShares MSCI Germany Index Fund

EAT WELL INVT GROUP INC by Eat Well Investment Group Inc.

Eat Well Investment Group Inc

iShares Trust MSCI Germany Small-Cap ETF

iShares MSCI Hong Kong Index Fund

iShares Inc iShares MSCI Italy ETF

EDINBURGH WORLDWIDE INVES by Edinburgh Worldwide Investment Trust plc

iShares MSCI Japan Index Fund

iShares MSCI Japan Value ETF

iShares Inc iShares MSCI Belgium ETF

EARTHWORKS ENTMT NEW by Earthworks Entertainment, Inc.

Earthworks Entertainment Inc

iShares Inc iShares MSCI Switzerland ETF

EWELLNESS HEALTHCARE CORP by eWellness Healthcare Corp

eWellness Healthcare Corp

Merion Inc

iShares MSCI Malaysia Index Fund

iShares MSCI Netherlands Index Fund

iShares Inc iShares MSCI Austria ETF

EASTWOOD BIO-MED CDA INC by Eastwood Bio-Med CDA Inc.

iShares Inc iShares MSCI Spain ETF

EMERGING WORLD PHARMA INC by Emerging World Pharma, Inc.

Emerging World Pharma Inc

EAST WEST PETE ORD by East West Petroleum Corp.

East West Petroleum Corp

iShares MSCI France Index Fund

EWORLD COMPANIES INC by eWorld Companies, Inc.

eWorld Companies Inc

iShares Inc iShares MSCI Singapore ETF

EWSB BANCORP INC by EWSB Bancorp, Inc.

iShares Inc iShares MSCI Taiwan ETF

Energy Web - United States Dollar

Edgewise Therapeutics, Inc. - Common Stock

Edgewise Therapeutics Inc

iShares MSCI United Kingdom ETF

iShares MSCI United Kingdom Small Cap ETF

ProShares UltraShort MSCI Japan

iShares Inc iShares MSCI Mexico ETF

SPDR S&P Emerging Markets Small Cap ETF

iShares Inc iShares MSCI South Korea ETF

iShares Inc iShares MSCI Brazil ETF

iShares MSCI Brazil Small-Cap ETF

On Wednesday,&nbsp;Boston Scientific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) released the results of the primary endpoint of the ACURATE IDE trial of&nbsp;ACURATE&nbsp;neo2 Aortic Valve System for patients with severe, symptomatic aortic stenosis at risk of <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/n41629382/acurate-neo2-aortic-valve-system-data-presented-at-late-breaking-clinical-trial-session-at-tct-202" rel="noreferrer noopener">open-heart surgery</a>.
The data were presented at Transcatheter Cardiovascular Therapeutics 2024, the annual scientific symposium of the Cardiovascular Research Foundation.
This randomized trial evaluated the ACURATE&nbsp;neo2 valve, the company&#8217;s second-generation transcatheter aortic valve replacement (TAVR) technology, versus a pre-defined control valve, either the commercially available SAPIEN valve or the Evolut transcatheter aortic valve system.
SAPIEN valve is sold by Edwards Lifesciences Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>), and Evolut is Medtronic Plc&#8217;s NYSE: MDT) brand.
The composite rate of all-cause mortality, stroke, or rehospitalization at one year was 16.16% in the ACURATE&nbsp;neo2 arm and 9.53% in the control arm, not meeting the prespecified criterion for non-inferiority (the posterior probability for non-inferiority was 77.9%, which is lower than the non-inferiority test threshold of 97.5%).
&#8220;This trial is the largest randomized comparison of TAVR platforms and was conducted over four years, including during a global pandemic that introduced complexities for enrollment,&#8221; said&nbsp;Michael Reardon, co-principal investigator of the ACURATE IDE trial.
The company also presented data from a post-hoc analysis to identify and evaluate expanded and under-expanded ACURATE&nbsp;neo2 valve frames within the ACURATE IDE trial.
The company reviewed key procedural factors, including pre-and post-dilation, which help prepare for, enable, and confirm proper valve expansion during the procedure.
Following this review, an assessment of implant quality for the ACURATE&nbsp;neo2 valve was initiated. The assessment highlighted that approximately 20% of the valves were under-expanded.
Data from the assessment also demonstrated that the rate of death, stroke, or rehospitalization at one year was similar between the ACURATE&nbsp;neo2 expanded group and the control group.
Boston Scientific continues to work closely with the U.S. Food and Drug Administration on the regulatory strategy for approval of the ACURATE valve platform in the U.S.
The ACURATE&nbsp;neo2 Aortic Valve System and the ACURATE Prime Aortic Valve System are approved in Europe.
In the&nbsp;U.S., the ACURATE&nbsp;neo2 Aortic Valve System and the ACURATE Prime Aortic Valve System are investigational devices.
Price Action: BSX stock is down 1.66% at $83.16 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41630458/cdw-shares-dip-as-q3-sales-miss-amid-weak-hardware-demand-and-customer-delays" target="_blank" rel="noreferrer noopener">CDW Shares Dip As Q3 Sales Miss Amid Weak Hardware Demand And Customer Delays</a></li>
</ul>

Large Cap

News

Health Care

Movers

Trading Ideas

General

Why is Boston Scientific Stock Trading Lower On Wednesday?

<a href="https://event.choruscall.com/mediaframe/webcast.html?webcastid=MY6v7nFk" title="https://event.choruscall.com/mediaframe/webcast.html?webcastid=MY6v7nFk">https://event.choruscall.com/mediaframe/webcast.html?webcastid=MY6v7nFk</a>

Shares Of Boston Scientific See Volume; Company To Provide Cardiology Business Update At 4:00 PM EDT

Biotech

TRISCEND II Trial Shows Edwards EVOQUE System Significantly Outperforms Medical Therapy Alone In Treating Severe Tricuspid Regurgitation, Achieving 95.3% TR Elimination And Marked Improvements In Symptoms And Quality Of Life At One Year; Results Published In NEJM And JACC

Benzinga's options scanner has just identified more than 10 option transactions on Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>), with a cumulative value of $336,522. Concurrently, our algorithms picked up 2 puts, worth a total of 107,477.
<h3>Predicted Price Range</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $67.5 to $82.5 for Edwards Lifesciences during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Edwards Lifesciences's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Edwards Lifesciences's whale trades within a strike price range from $67.5 to $82.5 in the last 30 days. 
<h3>Edwards Lifesciences Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730132130_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>EW</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$4.0</td>
<td>$3.8</td>
<td>$3.8</td>
<td>$72.50</td>
<td>$69.9K</td>
<td>326</td>
<td style="text-align: right;">185</td>
</tr>
<tr>
<td>EW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$3.3</td>
<td>$3.2</td>
<td>$3.3</td>
<td>$70.00</td>
<td>$45.5K</td>
<td>407</td>
<td style="text-align: right;">268</td>
</tr>
<tr>
<td>EW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$3.5</td>
<td>$3.3</td>
<td>$3.5</td>
<td>$70.00</td>
<td>$43.0K</td>
<td>407</td>
<td style="text-align: right;">20</td>
</tr>
<tr>
<td>EW</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$2.3</td>
<td>$2.25</td>
<td>$2.3</td>
<td>$67.50</td>
<td>$37.5K</td>
<td>1.0K</td>
<td style="text-align: right;">163</td>
</tr>
<tr>
<td>EW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$1.95</td>
<td>$1.3</td>
<td>$2.0</td>
<td>$77.50</td>
<td>$30.0K</td>
<td>913</td>
<td style="text-align: right;">150</td>
</tr>
</tbody>
</table>

<h3>About Edwards Lifesciences</h3>
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter valve technologies, surgical clips, and catheters. The firm derives about 55% of its total sales from outside the US.
In light of the recent options history for Edwards Lifesciences, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of Edwards Lifesciences</h3>
<ul>
<li>Currently trading with a volume of 4,192,400, the EW's price is up by 0.08%, now at $69.43. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 99 days.</li>
</ul>
<h3>Expert Opinions on Edwards Lifesciences</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $72.2.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from RBC Capital has decided to maintain their Outperform rating on Edwards Lifesciences, which currently sits at a price target of $75. 
&#x2A; An analyst from Piper Sandler persists with their Neutral rating on Edwards Lifesciences, maintaining a target price of $70. 
&#x2A; An analyst from Morgan Stanley downgraded its action to Equal-Weight with a price target of $70. 
&#x2A; An analyst from JP Morgan has decided to maintain their Neutral rating on Edwards Lifesciences, which currently sits at a price target of $78. 
&#x2A; An analyst from Baird has decided to maintain their Neutral rating on Edwards Lifesciences, which currently sits at a price target of $68. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Edwards Lifesciences, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Markets

Unpacking the Latest Options Trading Trends in Edwards Lifesciences

Edwards Lifesciences Says EARLY TAVR Trial Showed That Within The First 6-Months, 26.2% Of Patients In The Clinical Surveillance Arm Converted To AVR With Many Presenting Progressive Or Advanced Symptoms; In The 12-Month Follow-Up Period After Randomization, The Rate Of Conversion To AVR Was 47.2%

Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) today announced results from the EARLY TAVR Trial, the first randomized, controlled trial designed to study the best strategy for treating asymptomatic severe aortic stenosis (AS) and the benefits of early intervention with transcatheter aortic valve replacement (TAVR). The trial results demonstrated that asymptomatic severe AS patients randomized to Edwards TAVR experienced superior outcomes compared with guideline-recommended clinical surveillance. Trial investigators presented the data today during a late-breaking clinical trials session at Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation(CRF) and published simultaneously in The New England Journal of Medicine.
With a median follow up of 3.8 years, the data demonstrated superiority of early TAVR, with 26.8% of the 455 patients in the TAVR arm experiencing death, stroke or unplanned cardiovascular hospitalization compared to 45.3% of the 446 patients in the clinical surveillance arm. Additionally, the data showed that early intervention with TAVR:
<ul>
<li>Prevented unpredictable and rapid progression of symptoms, which sometimes resulted in emergent intervention and/or hospitalization;</li>
<li>Prevented clinically meaningful and rapid decline in quality of life; and</li>
<li>Resulted in numerically lower rate of stroke for patients with early TAVR (4.2% vs. 6.7% at a median follow-up time of 3.8 years).</li>
</ul>

Edwards Lifesciences Announces Results From The  EARLY TAVR Trial, The First Randomized, Controlled Trial Designed To Study The Best Strategy For Treating Asymptomatic Severe Aortic Stenosis And The Benefits Of Early Intervention With Transcatheter Aortic Valve Replacement

Stocks are ending the week on a high note, with tech leading the charge as investors position ahead of next week&#8217;s pivotal earnings releases from <a href="https://www.benzinga.com/topic/magnificent-7">five of the &#8220;Magnificent Seven&#8221; stocks.</a>
Microsoft Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NYSE">MSFT</a>), Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), and Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) will all report quarterly earnings between Oct. 29 and Oct. 31.
Combined, nearly 45% of the S&amp;P 500 by market cap is set to report results next week, with other heavyweights including McDonald&#8217;s Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>), Visa Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>), Eli Lilly and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), Mastercard Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>), Chevron Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) and Exxon Mobil Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>).
Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) continued its upward trajectory on Friday, rising 2.7% following a massive 21% jump on Thursday — its biggest one-day gain since May 2013.
The S&amp;P 500 was up 0.5% at midday trading in New York, while the Nasdaq 100 surged by 1.5%, fueled by semiconductor stocks. 
The Dow Jones Industrial Average fell 0.3%, on track to end a six-week winning streak. The U.S. dollar strengthened further, with the DXY Index rising past the 104 mark, setting up for a fourth straight week of gains. Meanwhile, Treasury yields were steady. 
WTI crude rose 1.8%, driven by concerns over geopolitical tensions in the Middle East. Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) is up slightly at $67,695.
<h1 class="wp-block-heading">Friday&#8217;s Performance In Major U.S. Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day % change</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>20,500.56</td>
<td>1.3%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,839.28</td>
<td>0.5%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,219.60</td>
<td>0.3%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>42,271.11</td>
<td>-0.3%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:50 p.m. ET</figcaption></figure>
According to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent102225&amp;t=be2bearmibe3na1">Benzinga Pro</a> data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 0.5% to $582.19.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;eased 0.2% to $423.18.</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) rallied 1.3% to $498.83.</li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) inched 0.2% up to $220.09.</li>
<li>The Technology Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) outperformed, up by 1.4%. The Utilities Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) lagged, down 0.9%.</li>
</ul>
<h1 class="wp-block-heading">Thursday&#8217;s Stock Movers</h1>
<ul>
<li>Capital One Financial Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COF#NYSE">COF</a>) rallied 7% to levels last seen in October 2021 on better-than-expected quarterly results. </li>
<li>Digital Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLR#NYSE">DLR</a>) rallied over 10% after reporting record new lease bookings. </li>
</ul>
Other stocks reacting to earnings included:
<ul>
<li>Ameriprise Financial Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMP#NYSE">AMP</a>), down 0.13%</li>
<li>DexCom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>), down 1%</li>
<li>ResMed Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>) up 7.6%, </li>
<li>Skechers U.S.A. Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKX#NYSE">SKX</a>) down 0.2%, </li>
<li>Western Digital Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>) up 7.6%, </li>
<li>Deckers Outdoor Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>), up 11%</li>
<li>Edward Lifesciences Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>), down by 0.6%</li>
<li>HCA Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>), down 10%, </li>
<li>Aon plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AON#NYSE">AON</a>), up 6%, </li>
<li>Colgate-Palmolive Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>), down 3.4%, </li>
<li>Centene Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>), up 6.7%, </li>
<li>Saia Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>), up 9.2%. </li>
</ul>
Read Now:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41549147/goldman-sachs-analyst-remains-bullish-on-boeing-despite-weak-q3-long-term-deep-valu">Goldman Sachs Analyst Remains Bullish On Boeing Despite Weak Q3: &#8216;Long-Term Deep-Value Opportunity</a>&#8216;</li>
</ul>
Photo: Shutterstock

Earnings

Equities

Macro Economic Events

Sector ETFs

Broad U.S. Equity ETFs

Econ #s

Economics

Tech

ETFs

$BTC

AAPL

AMZN

DECK

SPDR Dow Jones Industrial Average ETF Trust

DXCM

GOOG

GOOGL

MSFT

RIVN

SAIA

TSLA

Select Sector SPDR-Consumer Discretionary

Tech Stocks Rally As Investors Await Magnificent 7 Earnings; Dollar Eyes Fourth Straight Positive Week: What's Driving Markets Friday?

Canaccord Genuity analyst William Plovanic maintains Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) with a Hold and lowers the price target from $66 to $63.

Price Target

Analyst Ratings

Canaccord Genuity Maintains Hold on Edwards Lifesciences, Lowers Price Target to $63

JP Morgan analyst Robbie Marcus maintains Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) with a Neutral and raises the price target from $72 to $78.

JP Morgan Maintains Neutral on Edwards Lifesciences, Raises Price Target to $78

Piper Sandler analyst Adam Maeder maintains Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) with a Neutral and lowers the price target from $73 to $70.

Piper Sandler Maintains Neutral on Edwards Lifesciences, Lowers Price Target to $70

Truist Securities analyst Richard Newitter maintains Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) with a Hold and lowers the price target from $71 to $70.

Truist Securities Maintains Hold on Edwards Lifesciences, Lowers Price Target to $70

Providing a diverse range of perspectives from bullish to bearish, 12 analysts have published ratings on Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) in the last three months.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $74.33, a high estimate of $90.00, and a low estimate of $66.00. This current average has decreased by 11.23% from the previous average price target of $83.73. 
<img src="https://www.benzinga.com/files/images/story/2024/1729861232_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Edwards Lifesciences. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Rescott</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$68.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$70.00</td>
<td>-</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$75.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$66.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$70.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$77.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Matthew Taylor</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$70.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$71.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Suraj Kalia</td>
<td>Oppenheimer</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Danielle Antalffy</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$75.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$80.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$80.00</td>
<td>$90.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Edwards Lifesciences. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Edwards Lifesciences compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Edwards Lifesciences's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Edwards Lifesciences's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/EW/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Edwards Lifesciences analyst ratings.</a>
<h2>About Edwards Lifesciences</h2>
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter valve technologies, surgical clips, and catheters. The firm derives about 55% of its total sales from outside the US.
<h3>Edwards Lifesciences: Financial Performance Dissected</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Edwards Lifesciences's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 6.98%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Edwards Lifesciences's net margin is impressive, surpassing industry averages. With a net margin of 26.43%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Edwards Lifesciences's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 5.03%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Edwards Lifesciences's ROA excels beyond industry benchmarks, reaching 3.69%. This signifies efficient management of assets and strong financial health.
Debt Management: Edwards Lifesciences's debt-to-equity ratio is below the industry average. With a ratio of 0.09, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: What Are They?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cracking The Code: Understanding Analyst Reviews For Edwards Lifesciences

Baird analyst David Rescott maintains Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) with a Neutral and lowers the price target from $73 to $68.

Baird Maintains Neutral on Edwards Lifesciences, Lowers Price Target to $68

With U.S. stock futures trading slightly higher this morning on Friday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects AutoNation, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AN#NYSE">AN</a>) to report quarterly earnings at $4.38 per share on revenue of $6.71 billion before the opening bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. AutoNation shares gained 0.4% to $163.81 in after-hours trading.</li>
<li>Capital One Financial Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COF#NYSE">COF</a>) reported better-than-expected third-quarter results.&nbsp; The company reported quarterly earnings of $4.51 per share, which beat the analyst consensus estimate of $3.76. Quarterly revenue came in at $10.014 billion, which beat the analyst consensus estimate of $9.861 billion. Capital One Financial shares climbed 4.9% to $160.71 in the after-hours trading session.</li>
<li>Analysts are expecting Colgate-Palmolive Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>) to post quarterly earnings at 89 cents per share on revenue of $5.00 billion. The company will release earnings before the markets open. Colgate-Palmolive shares gained 0.7% to $100.40 in after-hours trading.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>Edwards Lifesciences Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) reported better-than-expected earnings for the third quarter, while sales missed estimates. Edwards Lifesciences shares fell 4.4% to $67.25 in the after-hours trading session.</li>
<li>Analysts expect HCA Healthcare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) to report quarterly earnings at $4.96 per share on revenue of $17.54 billion before the opening bell. HCA Healthcare shares fell 1% to $395.00 in after-hours trading.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41516113/how-to-earn-500-a-month-from-weyerhaeuser-stock-ahead-of-q3-earnings">How To Earn $500 A Month From Weyerhaeuser Stock Ahead Of Q3 Earnings</a></li>
</ul>
Photo courtesy: AutoNation

Pre-Market Outlook

AutoNation, Capital One Financial And 3 Stocks To Watch Heading Into Friday

Whales with a lot of money to spend have taken a noticeably bullish stance on Edwards Lifesciences.
Looking at options history for Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) we detected 14 trades.
If we consider the specifics of each trade, it is accurate to state that 42% of the investors opened trades with bullish expectations and 42% with bearish.
From the overall spotted trades, 4 are puts, for a total amount of $169,256 and 10, calls, for a total amount of $439,821.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $60.0 and $80.0 for Edwards Lifesciences, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Edwards Lifesciences stands at 1511.31, with a total volume reaching 4,213.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Edwards Lifesciences, situated within the strike price corridor from $60.0 to $80.0, throughout the last 30 days.
<h3>Edwards Lifesciences 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729802747_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>EW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$2.05</td>
<td>$1.8</td>
<td>$1.8</td>
<td>$77.50</td>
<td>$147.0K</td>
<td>3.5K</td>
<td>1.2K</td>
</tr>
<tr>
<td>EW</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$1.6</td>
<td>$1.45</td>
<td>$1.45</td>
<td>$65.00</td>
<td>$72.5K</td>
<td>4.9K</td>
<td>708</td>
</tr>
<tr>
<td>EW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$7.4</td>
<td>$7.2</td>
<td>$7.2</td>
<td>$67.50</td>
<td>$41.7K</td>
<td>310</td>
<td>83</td>
</tr>
<tr>
<td>EW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$2.5</td>
<td>$2.45</td>
<td>$2.45</td>
<td>$77.50</td>
<td>$37.7K</td>
<td>147</td>
<td>154</td>
</tr>
<tr>
<td>EW</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$2.45</td>
<td>$0.9</td>
<td>$1.35</td>
<td>$60.00</td>
<td>$33.7K</td>
<td>1.1K</td>
<td>250</td>
</tr>
</tbody>
</table>

<h3>About Edwards Lifesciences</h3>
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter valve technologies, surgical clips, and catheters. The firm derives about 55% of its total sales from outside the US.
<h3>Present Market Standing of Edwards Lifesciences</h3>
<ul>
<li>With a trading volume of 6,662,255, the price of EW is up by 4.82%, reaching $74.01.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 0 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Edwards Lifesciences</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $71.6.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Citigroup continues to hold a Buy rating for Edwards Lifesciences, targeting a price of $77. 
&#x2A; An analyst from Evercore ISI Group persists with their In-Line rating on Edwards Lifesciences, maintaining a target price of $70. 
&#x2A; Reflecting concerns, an analyst from Morgan Stanley lowers its rating to Equal-Weight with a new price target of $70. 
&#x2A; Maintaining their stance, an analyst from RBC Capital continues to hold a Outperform rating for Edwards Lifesciences, targeting a price of $75. 
&#x2A; An analyst from Canaccord Genuity has decided to maintain their Hold rating on Edwards Lifesciences, which currently sits at a price target of $66. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Edwards Lifesciences with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

<h3>Gainers</h3>
<ul>
<li>Bionomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNOX#NASDAQ">BNOX</a>) shares rose 48.3% to $0.53 during Thursday's after-market session. The market value of their outstanding shares is at $7.0 million. </li>
<li>Lyell Immunopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYEL#NASDAQ">LYEL</a>) stock moved upwards by 32.92% to $1.45. The company's market cap stands at $370.9 million. </li>
<li>Reviva Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVPH#NASDAQ">RVPH</a>) shares rose 9.64% to $1.25. The market value of their outstanding shares is at $41.3 million. </li>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) shares increased by 8.74% to $0.87. The company's market cap stands at $20.7 million. </li>
<li>Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) shares increased by 7.32% to $75.5. The market value of their outstanding shares is at $45.4 billion. As per the press release, Q3 earnings came out today. </li>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) stock increased by 6.85% to $1.87. The market value of their outstanding shares is at $21.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) stock declined by 15.2% to $63.5 during Thursday's after-market session. The company's market cap stands at $25.4 billion. The company's, Q3 earnings came out today. </li>
<li>Quince Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNCX#NASDAQ">QNCX</a>) stock declined by 14.29% to $1.02. The market value of their outstanding shares is at $44.1 million. </li>
<li>Universal Health Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>) shares declined by 10.98% to $200.0. The company's market cap stands at $13.3 billion. As per the press release, Q3 earnings came out today. </li>
<li>Allakos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLK#NASDAQ">ALLK</a>) stock decreased by 6.65% to $1.11. The market value of their outstanding shares is at $98.7 million. </li>
<li>Catheter Precision (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#AMEX">VTAK</a>) stock fell 6.34% to $0.82. The market value of their outstanding shares is at $2.2 million. </li>
<li>Scorpius Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SCPX#AMEX">SCPX</a>) shares fell 5.55% to $0.71. The market value of their outstanding shares is at $2.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALLK

BNOX

LYEL

ONMD

QNCX

RVPH

SCPX

VTAK

12 Health Care Stocks Moving In Thursday's After-Market Session

Edwards Lifesciences Sees Q4 EPS $0.53-$0.57; Sales $1.33B-$1.39B

WIIM

Edwards Lifesciences shares are trading higher after the company reported better-than-expected Q3 adjusted EPS results.

Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) reported quarterly earnings of $0.67 per share which beat the analyst consensus estimate of $0.64 by 4.69 percent. The company reported quarterly sales of $1.354 billion which missed the analyst consensus estimate of $1.522 billion by 11.02 percent. This is a 8.58 percent decrease over sales of $1.481 billion the same period last year.

Earnings Beats

Earnings Misses

Edwards Lifesciences Q3 2024 Adj. EPS $0.67 Beats $0.64 Estimate, Sales $1.354B Miss $1.522B Estimate

Tech stocks outperformed on Thursday, driven by Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), which skyrocketed 18% in midday trading following stronger-than-<a href="https://www.benzinga.com/news/24/10/41515376/tesla-to-rally-more-than-24-here-are-10-top-analyst-forecasts-for-thursday">expected quarterly financial results. </a>
The electric vehicle giant is on track for its best session since March 2021.
Despite Tesla&#8217;s spectacular rally, broader market sentiment remained cautious, reflecting recent trends of subdued risk appetite.
In macroeconomic news, weekly jobless claims dropped significantly, coming in below expectations and suggesting ongoing resilience <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41517353/jobless-claims-fall-more-than-expected-continuing-benefits-surge-to-nearly-3-year-h">in the labor market. </a>
Meanwhile, private sector activity surveys revealed better-than-expected conditions in both services and manufacturing this month and a further <a href="https://www.benzinga.com/economics/macro-economic-events/24/10/41520604/us-private-sector-growth-remains-strong-in-october-price-pressures-now-consistent">reduction in price pressures. </a>
Both the S&amp;P 500 and Russell 2000 traded flat, while the Dow Jones fell 0.6%. The consumer discretionary sector led gains, heavily influenced by Tesla's stellar performance.
The U.S. dollar softened slightly, and Treasury yields edged lower, easing pressure on gold. The SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>) rose 0.6%.
Oil prices dropped 1%, heading for a second consecutive day of losses. Meanwhile, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) gained 1.8%. 
<h3 class="wp-block-heading">Thursday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %change</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>20,164.58</td>
<td>0.5%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,796.37</td>
<td>0.0%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,207.55</td>
<td>0.0% </td>
</tr>
<tr>
<td>Dow Jones</td>
<td>42,259.72</td>
<td>-0.6% </td>
</tr>
</tbody>
</table>
</figure>
According to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent102224&amp;t=be2bearmibe3na1">Benzinga Pro</a> data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) flattened at $577.32.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;fell 0.7% to $422.33.</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) rose 0.4% to $489.81.</li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) inched 0.1% down to $218.88.</li>
<li>The Consumer Discretionary Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) outperformed, up by 2.5%, predominately affected by Tesla. The Materials Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>) lagged, down 1.4%.</li>
</ul>
<h3 class="wp-block-heading">Thursday&#8217;s Stock Movers</h3>
Stocks reacting to earnings results include: 
<ul>
<li>T-Mobile US Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>), up over 4%, </li>
<li>International Business Machines Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>), down over 6%,</li>
<li>ServiceNow Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>), up over 5%,</li>
<li>Lam Research Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>), up 3.8%,</li>
<li>Newmont Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>), down over 9%,</li>
<li>United Rentals Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/URI#NYSE">URI</a>), down 2%,</li>
<li>Las Vegas Sands Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LVS#NYSE">LVS</a>), up 1.3%,</li>
<li>Raymond James Financial Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RJF#NYSE">RJF</a>), up over 7%,</li>
<li>S&amp;P Global Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPGI#NYSE">SPGI</a>), down 2.4%,</li>
<li>Union Pacific Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNP#NYSE">UNP</a>), down 5%, </li>
<li>Honeywell International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HON#NASDAQ">HON</a>), down 4.4%, </li>
<li>KKR &amp; Co. Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>), up 3.4%, </li>
<li>United Parcel Service Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>), up 5.1%, </li>
<li>Carrier Global Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CARR#NYSE">CARR</a>), down 7%, </li>
<li>Nasdaq Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>), up 1.6%, </li>
<li>Valero Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLO#NYSE">VLO</a>), up 0.7%, </li>
<li>CBRE Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CBRE#NYSE">CBRE</a>) up by over 9%, </li>
<li>Dow Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>), down 1.1%,</li>
</ul>
<ul>
<li>Southwest Airlines Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>) dropped over 3%, despite posting better-than-expected results and reaching a deal with Elliott Investment Management on the board&#8217;s composition. However, the CEO warned of potential delivery delays due to Boeing Co.&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) ongoing machinist strike.</li>
</ul>
Large-cap companies slated to report results after the close include Capital One Financial Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COF#NYSE">COF</a>), Ameriprise Financial Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMP#NYSE">AMP</a>), Edward Lifesciences Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>), ResMed Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RES#NYSE">RES</a>), DexCom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>), and Deckers Outdoor Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>). 
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41515619/delivery-giant-ups-breaks-revenue-miss-streak-after-10-quarters-stock-soars">Delivery Giant UPS Breaks Revenue-Miss Streak After 10 Quarters, Stock Soars</a></li>
</ul>
Image created using artificial intelligence via MidJourney .

Mid Cap

Small Cap

CARR

CBRE

LRCX

NDAQ

SPGI

TMUS

XLRE

Tech Stocks Rebound, Tesla Marks Best 1-Day Gain Since March 2021, Gold Rises As Treasury Yields Ease: What's Driving Markets Thursday?

Joanne Wuensch, an analyst from Citi, maintained the Buy rating on Edwards Lifesciences (EW – Research Report). The associated price target was rai...

Promising EARLY TAVR Trial Results Boost Edwards Lifesciences' Outlook with 16.7% Projected Share Price Growth

Bullish option flow detected in Edwards Lifesciences (EW) with 6,442 calls trading, 3x expected, and implied vol increasing over 3 points to 36.21%...

Edwards Lifesciences call volume above normal and directionally bullish

Raymond James notes that investigators presented EARLY TAVR data at the transcatheter Cardiovascuar Therapeutics confidence. The trial studied the ...

Raymond James says Edwards' EARLY TAVR data also positive for Medtronic, Abbott

Piper Sandler analyst Adam Maeder maintained a Hold rating on Edwards Lifesciences (EW – Research Report) today and set a price target of $70.00. T...

Piper Sandler Reaffirms Their Hold Rating on Edwards Lifesciences (EW)

Edwards Lifesciences (EW – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Larry Biegels...

Promising EARLY TAVR Trial Results Bolster Buy Rating for Edwards Lifesciences

Edwards Lifesciences (EW) announced that the EVOQUE system demonstrated superiority compared to medical therapy alone for the one-year primary endp...

Edwards Lifesciences Evoque demonstrated superiority vs. medical therapy alone

Edwards Life says pivotal study for Evoque hit one-year goal

Bullish option flow detected in Edwards Lifesciences (EW) with 5,859 calls trading, 1.5x expected, and implied vol increasing over 3 points to 36.0...

Bullish option flow detected in Edwards Lifesciences (EW) with 6,927 calls trading, 1.9x expected, and implied vol increasing almost 5 points to 34...

Medtech shouldn't be greatly impacted by RFK Jr. at HHS, Wells Fargo says

ALGN

Press Releases

Edwards Lifesciences Corporation Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - EW

Legal

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Edwards Lifesciences Corporation

Edwards Lifesciences (EW) Faces Investor Class Action Over Loss of $16 Billion Of Market Capitalization – Hagens Berman

EW Investors Have Opportunity to Lead Edwards Lifesciences Corporation Securities Fraud Lawsuit

EW FRAUD ALERT: Suffer Losses on Your Edwards Lifesciences Securities? Contact BFA Law before December 13 Securities Fraud Class Action Deadline (NYSE:EW)

EW Equity Alert:  Kessler Topaz Meltzer & Check, LLP Alerts Shareholders of Securities Fraud Class Action Lawsuit Filed against Edwards Lifesciences Corporation

ROSEN, A TOP-RANKED LAW FIRM, Encourages Edwards Lifesciences Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – EW

Kessler Topaz Meltzer & Check, LLP Notifies Edwards Lifesciences Corporation Investors of Upcoming Deadline in Securities Fraud Class Action Lawsuit

EW INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Edwards Lifesciences Corporation Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit

Comments

Edwards Lifesciences

Intérêt court

Edwards Lifesciences (NYSE:EW) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL